Icecure Medical Ltd (ICCM) Stock Price, Trades & News

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	58.38
Equity-to-Asset	0.64
Debt-to-Equity	0.02
Debt-to-EBITDA	-0.01
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-13.55	Distress Grey Safe
Beneish M-Score	-2.64	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-13.4
	3-Year EBITDA Growth Rate	18.9
	3-Year EPS without NRI Growth Rate	19
	3-Year FCF Growth Rate	17
	3-Year Book Growth Rate	-39
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	33.32
	Future 3-5Y Total Revenue Growth Rate Estimate	97.61

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	49.73
	9-Day RSI	52
	14-Day RSI	50.54
	3-1 Month Momentum %	-41.94
	6-1 Month Momentum %	-65.92
	12-1 Month Momentum %	-77.26

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.52
	Quick Ratio	1.97
	Cash Ratio	1.69
	Days Inventory	398.47
	Days Sales Outstanding	23.16
	Days Payable	165.11

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-16.3
	Shareholder Yield %	-82.92

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	36.55
	Operating Margin %	-439.94
	Net Margin %	-441.6
	EBITDA Margin %	-432.23
	FCF Margin %	-417.62
	OCF Margin %	-415.34
	ROE %	-220.23
	ROA %	-123.07
	ROIC %	-268.27
	3-Year ROIIC %	191.72
	ROC (Joel Greenblatt) %	-1141.32
	ROCE %	-218.13
	Moat Score	2
	Tariff Resilience Score	5

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	3.78
	PB Ratio	1.88
	Price-to-Tangible-Book	1.88
	EV-to-EBIT	-0.78
	EV-to-EBITDA	-0.8
	EV-to-Revenue	3.45
	EV-to-Forward-Revenue	1.67
	EV-to-FCF	-0.83
	Price-to-GF-Value	0.28
	Price-to-Net-Current-Asset-Value	2.19
	Price-to-Net-Cash	4.85
	Earnings Yield (Greenblatt) %	-128.21
	FCF Yield %	-73.46

GF Value™: $21.37

ICCM

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with ICCM. Try a 7-Day Free Trial to check it out.

Icecure Medical Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Icecure Medical Ltd Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-11-19 10:00	In 145 days
Third quarter earnings results for 2026	2026-11-19	In 144 days
General meeting for 2025	2026-08-20 18:30	In 54 days
Second quarter earnings conference call for 2026	2026-08-13 11:00	In 47 days
Second quarter earnings results for 2026	2026-08-13	In 46 days
0.0333333:1 Stock Split	2026-06-04	4.55 (+16.69%)
First quarter earnings conference call for 2026	2026-05-12 11:00	7.20 (-2.83%)
First quarter earnings results for 2026	2026-05-12	7.20 (-2.83%)
Fourth quarter earnings conference call for 2025	2026-03-17 11:00	21.90 (+7.96%)
Annual report for 2025	2026-03-17	21.90 (+7.96%)

Show

Entries

Guru Commentaries on NAS:ICCM

No articles.

Press Release

	Subject	Date
	IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement	2026-06-25
	IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer	2026-06-23
	IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor	2026-06-17
	IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance	2026-06-17
	IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance	2026-06-02
	IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked	2026-05-19
	IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement	2026-05-13
	IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America	2026-05-12
	IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025	2026-04-21
	IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement	2026-03-26

10/Page

Articles on Icecure Medical Ltd

No articles.

Headlines

Jun 25, 2026

IceCure regains compliance with Nasdaq

Seeking Alpha • 7:52am

Jun 17, 2026

IceCure Stock Surges After 70% ProSense Install Increase

Benzinga • 11:45am

Crude Oil Edges Higher; US Retail Sales Top Estimates

Benzinga • 11:06am

Jun 02, 2026

IceCure Medical to boost share price with 1-for-30 reverse split to regain Nasdaq compliance

Seeking Alpha • 8:49am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.